Alpha 2.0
Login Register
» Authors » Louis van de Locht

Louis van de Locht

Explore the profile of Louis van de Locht including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 157
Followers 0
Related Specialties
Hematology
General Medicine
Oncology
Top 10 Co-Authors
Joop H Jansen
Bert A van der Reijden
Theo de Witte
Scott W Hiebert
Evelyn Tonnissen
Genyan Yang
Carsten Muller-Tidow
D Wade Clapp
Waleed Khalaf
Harry Dolstra
Published In
Nat Med
Ann Hematol
Br J Haematol
J Immunother
Clin Cancer Res
Affiliations
Soon will be listed here.
Recent Articles
1.
Expression of C-IAP1, C-IAP2 and SURVIVIN discriminates different types of lymphoid malignancies
de Graaf A, van Krieken J, Tonnissen E, Wissink W, van de Locht L, Overes I, et al.
Br J Haematol . 2005 Sep; 130(6):852-9. PMID: 16156855
(De-)regulation of apoptosis plays an important role in normal and malignant lymphopoiesis. Apoptosis-regulating genes of the BCL-2 family and the recently identified inhibitors of apoptosis (IAP) family have been implicated...
2.
Transcriptional repression of the Neurofibromatosis-1 tumor suppressor by the t(8;21) fusion protein
Yang G, Khalaf W, van de Locht L, Jansen J, Gao M, Ann Thompson M, et al.
Mol Cell Biol . 2005 Jul; 25(14):5869-79. PMID: 15988004
Von Recklinghausen's disease is a relatively common familial genetic disorder characterized by inactivating mutations of the Neurofibromatosis-1 (NF1) gene that predisposes these patients to malignancies, including an increased risk for...
3.
Intratumoral administration of recombinant human interleukin 12 in head and neck squamous cell carcinoma patients elicits a T-helper 1 profile in the locoregional lymph nodes
Van Herpen C, Looman M, Zonneveld M, Scharenborg N, de Wilde P, van de Locht L, et al.
Clin Cancer Res . 2004 Apr; 10(8):2626-35. PMID: 15102664
The objective of this Phase II study was to evaluate the pharmacodynamic and immune effects of intratumorally administered recombinant human interleukin-12 (IL-12) on regional lymph nodes, primary tumor, and peripheral...
4.
Epigenetic regulation of tumor suppressors in t(8:21)-containing AML
Yang G, Khalaf W, van de Locht L, Jansen J, van der Reijden B, Muller-Tidow C, et al.
Ann Hematol . 2004 Mar; 83(6):329-30. PMID: 15052372
The t(8;21) is perhaps the most frequent chromosomal translocation associated with acute myeloid leukemia. The translocation creates a fusion protein that consists of the DNA binding domain of the RUNX1...
5.
Rapid identification of CBFB-MYH11-positive acute myeloid leukemia (AML) cases by one single MYH11 real-time RT-PCR
van der Reijden B, Massop M, Tonnissen E, van de Locht L, Muus P, de Witte T, et al.
Blood . 2003 Jun; 101(12):5085-6. PMID: 12788791
No abstract available.
6.
Biodistribution and retention time of retrovirally labeled T lymphocytes in mice is strongly influenced by the culture period before infusion
Kolen S, Dolstra H, van de Locht L, Braakman E, Schattenberg A, de Witte T, et al.
J Immunother . 2002 Sep; 25(5):385-95. PMID: 12218776
T lymphocytes used for adoptive immunotherapy are often cultured before transfer to generate sufficient amounts of effector cells with desired specificity. Modification of lymphocytes induced by in vitro activation and...
7.
The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia
Linggi B, Muller-Tidow C, van de Locht L, Hu M, Nip J, Serve H, et al.
Nat Med . 2002 Jul; 8(7):743-50. PMID: 12091906
The t(8;21) is one of the most frequent chromosomal translocations associated with acute leukemia. This translocation creates a fusion protein consisting of the acute myeloid leukemia-1 transcription factor and the...